Cures and patent expirations are hitting this biopharmaceutical company in three different revenue streams; is Gilead Sciences a buy?
May 24, 2021
These two companies have emerged ahead of their competitors in having a medical intervention for the coronavirus epidemic.
Mar 6, 2020
We take care of the first one so you can focus on the other two!
Gilead released a mixed fourth-quarter earnings report. Longer-term investors should stick with the stock.
Feb 12, 2020
